Mark Coleman - 27 May 2025 Form 4 Insider Report for Axsome Therapeutics, Inc. (AXSM)

Role
Director
Signature
/s/ Herriot Tabuteau, M.D., Attorney-in-Fact
Issuer symbol
AXSM
Transactions as of
27 May 2025
Net transactions value
-$783,375
Form type
4
Filing time
29 May 2025, 19:00:05 UTC
Previous filing
20 May 2025
Next filing
10 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Coleman Mark Director C/O AXSOME THERAPEUTICS, INC., ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK /s/ Herriot Tabuteau, M.D., Attorney-in-Fact 29 May 2025 0001658379

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AXSM Common Stock Sale $395,512 -3,750 -6.9% $105.47 50,387 27 May 2025 Direct F1, F2, F3
transaction AXSM Common Stock Sale $387,862 -3,750 -7.4% $103.43 46,637 28 May 2025 Direct F1, F2, F4
holding AXSM Common Stock 403,856 27 May 2025 See Footnote F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the sale of underlying shares of previously exercised stock options.
F2 Such transaction was pursuant to a pre-approved 10b5-1 plan.
F3 Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $104.75 and $106.50.
F4 Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $102.71 and $104.38.
F5 Such shares are held by an entity, of which the reporting person has voting and dispositive power, and therefore, the reporting person is deemed to be the indirect beneficial owner of such shares.